Kite Pharma
Kite Presents New Data for Yescarta (axicabtagene ciloleucel) CAR T-cell Therapy Highlighting Manufacturing Excellence and Cost-Effectiveness in the US
Data Highlights Industry-leading Manufacturing Success Rates for US Axicabtagene Ciloleucel Patients from Launch to Present Data Also Supports Cost-effectiveness of Axicabtagene Ciloleucel Versus Bispecific Antibodies 16 February 2024 – Stockley Park, UK – Kite, a Gilead Company, will present new data for Yescarta (axicabtagene ciloleucel) at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings...
Real-World Evidence Demonstrates Feasibility and Safety of Outpatient Administration of Yescarta (axicabtagene ciloleucel)
Findings show comparable safety for patients administered axicabtagene ciloleucel in the outpatient setting in the US to inpatient infusion Real-world evidence supports further exploration of use of outpatient administration of chimeric antigen receptor T-cell (CAR T-cell) therapy to improve health system capacity. 15 February 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today...
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers
At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world Evidence (RWE) Shows Effectiveness in Adult R/R MCL with a Complete Response Rate of 81% and 84% for High-risk Features (Patients with TP53 /17p Deletion)...
Kite’s CAR T-Cell Therapy YESCARTA (Axicabtagene Ciloleucel) Compared with Bispecifics in R/R DLBCL in Two Analyses at ESMO 2023
23 October 2023 -- Stockley Park, UK -- Kite, a Gilead Company, today announced results from two indirect comparative analyses of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) versus bispecific antibodies epcoritamab and glofitamab, respectively, for the treatment of relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL), during the European Society for Medical Oncology (ESMO) Congress,...
REAL-WORLD RESULTS DEMONSTRATE HIGH RESPONSE RATE AND DURABLE REMISSION WITH KITE CAR T-CELL THERAPIES FOR R/R MCL AND FL AT EHA 2023
Stockley Park, UK - Kite, a Gilead Company, today announced results from two real-world studies that support the use of Yescarta (axicabtagene ciloleucel) in relapsed/refractory (R/R) follicular lymphoma (FL) (abstract S223) and Tecartus (brexucabtagene autoleucel) in R/R mantle cell lymphoma (MCL) (abstract 220). The results are presented at the European Hematology Association (EHA) 2023 Annual...
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Stockley Park, UK - 3 November 2022 - Gilead Sciences, Inc. and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL) and two oral presentations on investigator-sponsored studies in acute myeloid leukaemia (AML), during the 64th Annual American Society of Hematology (ASH) Annual Meeting (10-13 December).
KITE‪S CAR T-CELL THERAPY YESCARTA (AXICABTAGENE CILOLEUCEL) FIRST IN EUROPE TO RECEIVE POSITIVE CHMP OPINION FOR USE IN SECOND-LINE DIFFUSE LARGE B-CELL LYMPHOMA AND HIGH-GRADE B-CELL LYMPHOMA
Stockley Park, UK - 16 September, 2022 - Kite, a Gilead Company, today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12...
KITE‪S CAR T-CELL THERAPY TECARTUS (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)
Stockley Park, UK - 7 September 2022 - Kite, a Gilead Company, today announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (ALL).
KITE‪S CAR T-CELL THERAPY TECARTUS (BREXUCABTAGENE AUTOLEUCEL) RECEIVES POSITIVE CHMP OPINION IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA
Stockley Park, UK - 22 July 2022 - Kite, a Gilead Company, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell...
Kite, a Gilead Company, Continues to Advance Research With Longest CAR T Cell Therapy Follow-up Data at the 4th European CAR T-cell Meeting
ï Pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphoma ï Safety management data in relapsed/refractory diffuse large B cell lymphoma
